Search / Trial NCT05221580

China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
Launched by NOVO NORDISK A/S · Feb 2, 2022

Download PDF

Apply for Trial

Trial Information

Current as of May 18, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

Inclusion Criteria:
• 1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• 2. The decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on the approved Ryzodeg® label in China and independently from the decision to include the patient in this study.
• 3. Male or female, age above or equal to 18 years at the time of signing informed consent.
• 4. Diagnosed with T2DM and treated with any anti-hyperglycaemic medication(s) other than Ryzodeg® for at least 20 weeks prior to Treatment Initiation Visit (Visit 1).
• 5. Available and documented Glycosylated haemoglobin (HbA1c) value below or equal to 12 weeks prior to Informed Consent and Treatment Initiation Visit (Visit 1).
Exclusion Criteria:
• 1. Previous participation in this study. Participation is defined as having given informed consent in this study.
• 2. Treatment with any investigational drug within 30 days prior to enrolment into the study.
• 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
• 4. Known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved Ryzodeg® label in China.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.

Locations

Tianjin, Tianjin, China

Shanghai, Shanghai, China

Lanzhou, Gansu, China

Dalian, Liaoning, China

Huai'an, Jiangsu, China

Nanchong, Sichuan, China

Handan, Hebei, China

Haikou, Hainan, China

Harbin, Heilongjiang, China

Shenyang, Liaoning, China

Beijing, Beijing, China

Nanjing, Jiangsu, China

Hefei, Anhui, China

Chongqing, Chongqing, China

Jiangmen, Guangdong, China

Shantou, Guangdong, China

Shenzhen, Guangdong, China

Yangjiang, Guangdong, China

Yulin, Guangxi, China

Cangzhou, Hebei, China

Qinhuangdao, Hebei, China

Zhengzhou, Henan, China

Shiyan, Hubei, China

Wuhan, Hubei, China

Changsha, Hunan, China

Chifeng, Inner Mongolia Autonomous Region, China

Tongliao, Inner Mongolia Autonomous Region, China

Changshu, Jiangsu, China

Nantong, Jiangsu, China

Yixing, Jiangsu, China

Jilin, Jilin, China

Songyuan, Jilin, China

Huludao, Liaoning, China

Jinzhou, Liaoning, China

Yinchuan, Ningxia Hui Autonomous Region, China

Xining, Qinghai, China

Hanzhong, Shaanxi, China

Taiyuan, Shaanxi, China

Xi'an, Shaanxi, China

Weifang, Shandong, China

Yantai, Shandong, China

Zhibo, Shandong, China

Mang, Yunnan, China

Qujing, Yunnan, China

Hangzhou, Zhejiang, China

Shaoxing, Zhejiang, China